AegirBio AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 0.31 million compared to SEK 5.26 million a year ago. Net loss was SEK 13.43 million compared to SEK 24.61 million a year ago. Basic loss per share from continuing operations was SEK 0.64 compared to SEK 1.73 a year ago.
For the nine months, sales was SEK 1.7 million compared to SEK 11.87 million a year ago. Net loss was SEK 44.95 million compared to SEK 48.89 million a year ago. Basic loss per share from continuing operations was SEK 2.35 compared to SEK 3.43 a year ago.